The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; SERVIER
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Exelixis; Imvax; Lilly; Merck; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Ralf-Dieter Hofheinz
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Deutsche Krebshilfe (Inst); Merck (Inst); Sanofi (Inst)
 
Elena Elez
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Drew W. Rasco
Research Funding - Abbvie (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Takeda (Inst)
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Agios; AstraZeneca; Eisai; GRAIL
Travel, Accommodations, Expenses - Agios; AstraZeneca; Eisai; Genentech/Roche
 
Lin Shen
No Relationships to Disclose
 
Elizabeth Dowling
Employment - Boehringer Ingelheim
 
Shorena Archuadze
Employment - Boehringer Ingelheim
 
Bruna Andrade de Pereira
Employment - Boehringer Ingelheim
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Ipsen; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)